ADORE trial enrolls first patient

The pharmaceutical company Ferrer has announced that the first patient has been…

Words Lucie van Leeuwen.Published November 16, 2021
ADORE trial enrolls first patient

The pharmaceutical company Ferrer has announced that the first patient has been enrolled in their ADORE (ALS Deceleration with ORal Edaravone) clinical trial. This Phase III trial will enrol about 300 patients across European countries. It will evaluate how effective and safe FNP122 (an oral formulation of edaravone) is in people living with ALS. TRICALS is pleased to be working together with Ferrer on this trial. The full press release can be found here.

Prof. Leonard H. van den Berg, Chair of TRICALS and Principal Investigator of the study: “The TRICALS consortium is proud to collaborate with Ferrer, since this is an important study, and we look forward to offering further support throughout the course of the trial. We hope oral edaravone will yield a positive outcome and be beneficial for people diagnosed with ALS, as more effective treatments are needed”.

We will post updates on our website once they are available. Would you like to receive news about this trial and other TRICALS activities in your inbox? Click here to subscribe to our newsletter: https://bit.ly/news-letter-TRICALS!


Share

Related news

Results ADORE study: no effect of medication
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE […]
34th International Symposium on ALS/MND
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all […]
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during […]
Over 200 patients participate in Lighthouse II study worldwide
Over 200 patients participate in Lighthouse II study worldwide
The Lighthouse II study is a phase 3 clinical trial that compares […]